The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy, and the agents, both commercially available and investigational, used to treat malignant diseases.
Get full access to this article
View all access options for this article.
References
1.
BaselgaJ, RischinD, RansonM, Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J Clin Oncol.2002;20(21): 4292–4302.
2.
NakagawaK, TamuraT, NegoroS, Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib (Iressa, ZD1839) in Japanese patients with solid malignant tumors. Ann Oncol.2003;14(6):922–930.
ChenA, SolimandoD, WaddellJ.Gefitinib, fluorouracil, oxaliplatin and leucovorin (IFOX) regimen for colorectal cancer. Hosp Pharm.2013;48(11):905–911.
5.
DouillardJ, OstorosG, CoboM, First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: A phase-IV, open-label, single-arm study. Br J Cancer. 2014;110(1):55–62
6.
KimE, HirshV, MokT, Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): A randomised phase III trial. Lancet. 2008;372(9652):1809–1818.
7.
ThatcherN, ChangA, ParikhP, Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: Results from a randomised, placebo-controlled, multicenter study (Iressa survival evaluation in lung cancer). Lancet. 2005;366(9496):1527–1537.
8.
SunJ, LeeK, KimS, Gefitinib versus pemetrexed as second-line treatment in patients with nonsmall cell lung cancer previously treated with platinum-based chemotherapy (KCSG-LU08-01). Cancer. 2012;118(24):6234–6242.
9.
FukuokaM, YanoS, GiacconeG, Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non–small-cell lung cancer. J Clin Oncol.2003; 21(12):2237–2246.
10.
GiacconeG, JohnsonDH, ManegoldC, A phase III clinical trial ZD1839 (“Iressa”) in combination with gemcitabine and cisplatin in chemotherapy-naive patients with advanced non-small cell lung cancer (INTACT-1). J Clin Oncol.2004; 22(5):777–784
11.
RodonJ, TawbiHA, ThomasAL, A phase I, multicenter, open-label, first-in-human, dose-escalation study of the oral smoothened inhibitor sonidegib (LDE225) in patients with advanced solid tumors. Clin Cancer Res2014;20(7):1900–1909.
12.
MigdenMR, GuminskiA, GutzmerR, Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): A multicenter, randomised, double-blind phase 2 trial. Lancet Oncol.2015;16(6):716–728.
